UBQLN2 sirna

UBQLN2 siRNA (Human)

Cat. Num. AAA8225144

• Gene Names: UBQLN2; DSK2; ALS15; CHAP1; N4BP4; PLIC2; HRIHFB2157
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: UBQLN2; UBQLN2 siRNA (Human); N4BP4; PLIC2; Ubiquilin-2; Chap1; DSK2 homolog; Protein linking IAP with cytoskeleton 2; PLIC-2; hPLIC-2; Ubiquitin-like product Chap1/Dsk2; UBQLN2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: UBQLN2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 624

• Applicable Applications for UBQLN2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human UBQLN2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for UBQLN2 sirna

siRNA to inhibit UBQLN2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 16753207
• NCBI GeneID: 29978
• NCBI Accession #: NP_038472.2
• NCBI GenBank Nucleotide #: NM_013444.3
• UniProt Accession #: Q9UHD9; O94798; Q5D027; Q9H3W6; Q9HAZ4
• Molecular Weight: 65,696 Da
• NCBI Official Full Name: ubiquilin-2
• NCBI Official Synonym Full Names: ubiquilin 2
• NCBI Official Symbol: UBQLN2
• NCBI Official Synonym Symbols: DSK2; ALS15; CHAP1; N4BP4; PLIC2; HRIHFB2157
• NCBI Protein Information: ubiquilin-2
• UniProt Protein Name: Ubiquilin-2
• Protein Family: Ubiquilin
• UniProt Gene Name: UBQLN2
• UniProt Synonym Gene Names: N4BP4; PLIC2; PLIC-2; hPLIC-2
• UniProt Entry Name: UBQL2_HUMAN

NCBI Description

This gene encodes an ubiquitin-like protein (ubiquilin) that shares high degree of similarity with related products in yeast, rat and frog. Ubiquilins contain a N-terminal ubiquitin-like domain and a C-terminal ubiquitin-associated domain. They physically associate with both proteasomes and ubiquitin ligases; and thus, are thought to functionally link the ubiquitination machinery to the proteasome to affect in vivo protein degradation. This ubiquilin has also been shown to bind the ATPase domain of the Hsp70-like Stch protein. [provided by RefSeq, Oct 2009]

Uniprot Description

UBQLN2: Increases the half-life of proteins destined to be degraded by the proteasome; may modulate proteasome-mediated protein degradation. Defects in UBQLN2 are the cause of amyotrophic lateral sclerosis type 15 with or without frontotemporal dementia (ALS15). A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. Patients with ALS15 may develop frontotemporal dementia.

Protein type: Ubiquitin conjugating system

Chromosomal Location of Human Ortholog: Xp11.21

Cellular Component: cytoplasm; plasma membrane; nucleus

Molecular Function: protein binding

Disease: Amyotrophic Lateral Sclerosis 15, With Or Without Frontotemporal Dementia